CHRONOLAB

CE

IVD

Glycated Hemoglobin

Latex turbidimetry

Quantitative determination of glycated hemoglobin ($HbAB_{1B}c$)

PACKAGING

Ref.: 101-0771	Cont.: 1 x 30 / 1 x 10 / 1 x 125 mL

Store 2 - 8º C.

CLINICAL SIGNIFICANCE

Throughout the circulatory life of the red cell, Hemoglobin A1c is formed continuously by the adduction of glucose to the N-terminal of the hemoglobin beta chain. This process, which is non-enzymatic, reflects the average exposure of hemoglobin to glucose over an extended period. In a classical study, Trivelli et al1 showed Hemoglobin A1c in diabetic subjects to be elevated 2-3 fold over the levels found in normal individuals. Several investigators have recommended that Hemoglobin A1c serve as an indicator of metabolic control of the diabetic, since Hemoglobin A1c levels approach normal values for diabetics in metabolic control.[2,3,4]

Hemoglobin A1c has been defined operationally as the "fast fraction" hemoglobins (HbA1a, A1b, A1c) that elute first during column chromatography with cation-exchange resins. The non-glycosylated hemoglobin, which consists of the bulk of the hemoglobin has been designated HbA0. The present procedure utilizes a antigen and antibody reaction to directly determine the concentration of the HbA1c.

PRINCIPLE OF THE METHOD

This method utilizes the interaction of antigen and antibody to directly determine the HbA1c in whole blood. Total hemoglobin and HbA1c have the same unspecific absorption rate to latex particles. When mouse antihuman HbA1c monoclonal antibody is added (R2), latex-HbA1c-mouse anti human HbA1c antibody complex is formed. Agglutination is formed when goat anti-mouse IgG polyclonal antibody interacts with the monoclonal antibody. The amount of agglutination is proportional to the amount of HbA1c absorbed on to the surface of latex particles. The amount of agglutination is measured as absorbance. The HbA1c value is obtained from a calibration curve.

REAGENTS

R1	Latex 0.13%, Buffer, stabilizer.
R2	Mouse anti-human HbA1c monoclonal antibody 0.05mg/ml, goat anti-mouse IgG polyclonal antibody 0.08mg/dl, Buffer, stabilizers.
R3 (Hemolysis reagent)	Water and stabilizers
Optional	Ref: 101-0769 HbA1c Calibrator. Ref: 101-0770 HbA1c Control.

PRECAUTIONS

All human specimens should be regarded as potentially biohazardous. Therefore, universal precautions should be used in specimen handling (gloves, lab garments, avoid aerosol production, etc.).

PREPARATION

R1, R2 and R3 are ready to use. Mix gently before use.

STORAGE AND STABILITY

All the components of the kit are stable until the expiration date on the label when stored tightly closed at 2-8º C and contaminations are prevented during their use. Do not use reagents over the expiration date.

R1 and R2 are stable for at least one month after opening stored at 2-8° C.

Hemoglobin A1c in whole blood collected with EDTA is stable for one week at 2-8° C.[5]

Reagent deterioration: Alterations in the physical appearance of the reagents or values of control materials outside of the manufacturer's acceptable range may be an indication of reagent instability.

ADDITIONAL EQUIPMENT

- Thermostatic bath at 37º C.
- Spectrophotometer or photometer thermostable at 37º C with a 660 nm filter.

SAMPLES

Special preparation of the patient is unnecessary. Fasting specimens are not required. No special additives or preservatives other than anticoagulants are required. Collect venous blood with EDTA using aseptic technique.

To determine HbA1c, a hemolysate must be prepared for each sample:

1. Dispense 1 mL Hemolysis Reagent into tubes labeled: Calibrator, Control, Patients, etc. Note: Plastic or glass tubes of appropriate size are acceptable.
2. Place 20 µL of well mixed whole blood into the appropriately labeled lyse reagent tube. Mix.
3. Allow to stand for 5 minutes or until complete lysis is evident. Hemolysates may be stored up to 10 days at 2-8° C.

PROCEDURE

1. Bring the R1 and R2 Reagent and the photometer (cuvette holder) to 37º C.
2. Assay conditions:
   Wavelength: 660 nm
   Temperature: 37º C
   Cuvette ligth path: 1 cm
3. Adjust the instrument to zero with distilled water.
4. Pipette into a cuvette:

R1 (µL)	360
CalibratorP (0 to 4) or sample (µL)	10

5. Mix and incubate 5 minutes.
6. Pippete into the cuvette:

R2 (µL)	120

7. Mix and read the absorbance after 5 minutes (AB_B) of the R2 addition.

Chronolab has instruction sheets for several automatic analyzers. Instructions for many of them are available on request.

CALCULATIONS

HbA1c concentration (%)

Plot (AB_B) obtained against the HbA1c concentration of each calibrator (1 to 4 Level). HbA1c percentage in the sample is calculated by interpolation of its (AB) in the calibration curve.

QUALITY CONTROL

HbA1c Control (ref: 101-0770) is recommended to monitor the performance of manual and automated assay procedures. **Controls require hemolysis pretreatment after being reconstituted.**

Each laboratory should establish its own Quality Control scheme and corrective actions if controls do not meet the acceptable tolerances.

CHRONOLAB SYSTEMS, S.L., Travessia Prat de la Riba 34 B, 08849 Sant Climent de Llobregat, Barcelona, Spain
Tel. +34 617722466, www.chronolab.com, e-mail: info@chronolab.com

REFERENCE VALUES

Recommended Values: less than 6% for a non-diabetic, less than 7% for glycemic control of a person with diabetes.

Each laboratory should establish its own expected values. In using Hemoglobin A1c to monitor diabetic patients, results should be interpreted individually. That is, the patient should be monitored against him or herself. There is a 3-4 week time lag before Hemoglobin A1c reflects changes in blood glucose level.

PERFORMANCE CHARACTERISTICS

1.Linearity: The Hemoglobin A1c assay range is 2.0%-16.0%.

2.Sensitivity: Sensitivity was investigated by reading the change in absorbance at 660nm for a saline sample and a whole blood sample with a known concentration. A 0.056 absorbance change is approximately equivalent to 1.0% HbA1c.

3.Precision:

	Intra-assay (n=20)			Inter-assay (n=20)		
Mean (g/dL)	5.970	8.490	12.21	5.945	8.335	12.15
SD	0.138	0.072	0.152	0.190	0.093	0.179
CV (%)	2.31	0.85	1.24	3.2	1.12	1.47

4. Correlation: Results obtained using this procedure (y) were compared to those obtained using a reference procedure (x) with similar characteristics. 40 samples of HbA1c were assayed. The correlation coefficient (r) was 0.988 and the regression equation $y = 0.983x + 0.140$.

The results of the performance characteristics depend on the analyzer used.

INTERFERENCES AND LIMITATIONS

1. Bilirubin to 50mg/dL, ascorbic acid to 50mg/dL, triglycerides to 2000mg/dL, carbamylated Hb to 7.5mmol/L and acetylated Hb to 5.0mmol/L do not interfere in this assay.
2. This assay should not be used as the unique test for the diagnosis of diabetes mellitus. Other tests must be also considered to establish a correct diagnosis.
3. Patient specimens should always be assayed using a calibration curve.
4. It has been reported that results may be inconsistent in patients who have the following conditions: opiate addiction, lead-poisoning, alcoholism, ingest large doses of aspirin.[6, 7, 8, 9]
5. It has been reported that elevated levels of HbF may lead to underestimation of HA1c and, that uremia does not interfere with HbA1c determination by immunoassay.[10] It has been reported that labile intermediates (Schiff base) are not detected and therefore, do not interfere with HbA1c determination by immunoassay.[5]
6. It has been determined that Hemoglobin variants HbA2, HbC and HbS do not interfere with this method.
7. Other very rare variants of hemoglobin (e.g. HbE) have not been assessed.

BIBLIOGRAPHY

1. Trivelli, L.A., Ranney, H.M., and Lai, H.T., New Eng. J. Med. 284,353 (1971).
2. Gonen, B., and Rubenstein, A.H., Diabetologia 15, 1 (1978).
3. Gabbay, K.H., Hasty, K., Breslow, J.L., Ellison, R.C., Bunn, H.F., and Gallop, P.M., J. Clin. Endocrinol. Metab. 44, 859 (1977).
4. Bates, H.M., Lab. Mang., Vol 16 (Jan. 1978).
5. Tietz, N.W., Textbook of Clinical Chemistry, Philadelphia, W.B. Saunders Company, p.794-795 (1999).
6. Ceriello, A., et al, Diabetologia 22, p. 379 (1982).
7. Little, R.R., et al, Clin. Chem. 32, pp. 358-360 (1986).
8. Fluckiger, R., et al, New Eng.J. Med. 304 pp. 823-827 (1981).
9. Nathan, D.M., et al, Clin. Chem. 29, pp. 466-469 (1983).
10. Engbaek, F., et al, Clin. Chem. 35, pp. 93-97 (1989).
11. American Diabetes Association: Clinical Practice Recommendations (Position Statement). Diabetes Care 24 (Suppl. 1): S33-S55, (2001).